OBJECTIVE: Anti-tumor necrosis factor alpha (anti-TNF) therapy is a mainstay of treatment in rheumatoid arthritis (RA). The aim of the present study was to test established RA genetic risk factors to determine whether the same alleles also influence the response to anti-TNF therapy. METHODS: A total of 1,283 RA patients receiving etanercept, infliximab, or adalimumab therapy were studied from among an international collaborative consortium of 9 different RA cohorts. The primary end point compared RA patients with a good treatment response according to the European League Against Rheumatism (EULAR) response criteria (n = 505) with RA patients considered to be nonresponders (n = 316). The secondary end point was the change from baseline in the level of disease activity according to the Disease Activity Score in 28 joints (triangle upDAS28). Clinical factors such as age, sex, and concomitant medications were tested as possible correlates of treatment response. Thirty-one single-nucleotide polymorphisms (SNPs) associated with the risk of RA were genotyped and tested for any association with treatment response, using univariate and multivariate logistic regression models. RESULTS: Of the 31 RA-associated risk alleles, a SNP at the PTPRC (also known as CD45) gene locus (rs10919563) was associated with the primary end point, a EULAR good response versus no response (odds ratio [OR] 0.55, P = 0.0001 in the multivariate model). Similar results were obtained using the secondary end point, the triangle upDAS28 (P = 0.0002). There was suggestive evidence of a stronger association in autoantibody-positive patients with RA (OR 0.55, 95% confidence interval [95% CI] 0.39-0.76) as compared with autoantibody-negative patients (OR 0.90, 95% CI 0.41-1.99). CONCLUSION: Statistically significant associations were observed between the response to anti-TNF therapy and an RA risk allele at the PTPRC gene locus. Additional studies will be required to replicate this finding in additional patient collections.
OBJECTIVE: Anti-tumor necrosis factor alpha (anti-TNF) therapy is a mainstay of treatment in rheumatoid arthritis (RA). The aim of the present study was to test established RA genetic risk factors to determine whether the same alleles also influence the response to anti-TNF therapy. METHODS: A total of 1,283 RApatients receiving etanercept, infliximab, or adalimumab therapy were studied from among an international collaborative consortium of 9 different RA cohorts. The primary end point compared RApatients with a good treatment response according to the European League Against Rheumatism (EULAR) response criteria (n = 505) with RApatients considered to be nonresponders (n = 316). The secondary end point was the change from baseline in the level of disease activity according to the Disease Activity Score in 28 joints (triangle upDAS28). Clinical factors such as age, sex, and concomitant medications were tested as possible correlates of treatment response. Thirty-one single-nucleotide polymorphisms (SNPs) associated with the risk of RA were genotyped and tested for any association with treatment response, using univariate and multivariate logistic regression models. RESULTS: Of the 31 RA-associated risk alleles, a SNP at the PTPRC (also known as CD45) gene locus (rs10919563) was associated with the primary end point, a EULAR good response versus no response (odds ratio [OR] 0.55, P = 0.0001 in the multivariate model). Similar results were obtained using the secondary end point, the triangle upDAS28 (P = 0.0002). There was suggestive evidence of a stronger association in autoantibody-positive patients with RA (OR 0.55, 95% confidence interval [95% CI] 0.39-0.76) as compared with autoantibody-negative patients (OR 0.90, 95% CI 0.41-1.99). CONCLUSION: Statistically significant associations were observed between the response to anti-TNF therapy and an RA risk allele at the PTPRC gene locus. Additional studies will be required to replicate this finding in additional patient collections.
Authors: Lindsey A Criswell; Raymond F Lum; Kevin N Turner; Blanche Woehl; Yuanqing Zhu; Jinyi Wang; Hemant K Tiwari; Jeffrey C Edberg; Robert P Kimberly; Larry W Moreland; Michael F Seldin; S Louis Bridges Journal: Arthritis Rheum Date: 2004-09
Authors: Chunyu Liu; Franak Batliwalla; Wentian Li; Annette Lee; Ronenn Roubenoff; Evan Beckman; Houman Khalili; Aarti Damle; Marlena Kern; Richard Furie; Josée Dupuis; Robert M Plenge; Marieke J H Coenen; Timothy W Behrens; John P Carulli; Peter K Gregersen Journal: Mol Med Date: 2008 Sep-Oct Impact factor: 6.354
Authors: Hye-Soon Lee; Annette T Lee; Lindsey A Criswell; Michael F Seldin; Christopher I Amos; John P Carulli; Cristina Navarrete; Elaine F Remmers; Daniel L Kastner; Robert M Plenge; Wentian Li; Peter K Gregersen Journal: Mol Med Date: 2008 May-Jun Impact factor: 6.354
Authors: Soumya Raychaudhuri; Elaine F Remmers; Annette T Lee; Rachel Hackett; Candace Guiducci; Noël P Burtt; Lauren Gianniny; Benjamin D Korman; Leonid Padyukov; Fina A S Kurreeman; Monica Chang; Joseph J Catanese; Bo Ding; Sandra Wong; Annette H M van der Helm-van Mil; Benjamin M Neale; Jonathan Coblyn; Jing Cui; Paul P Tak; Gert Jan Wolbink; J Bart A Crusius; Irene E van der Horst-Bruinsma; Lindsey A Criswell; Christopher I Amos; Michael F Seldin; Daniel L Kastner; Kristin G Ardlie; Lars Alfredsson; Karen H Costenbader; David Altshuler; Tom W J Huizinga; Nancy A Shadick; Michael E Weinblatt; Niek de Vries; Jane Worthington; Mark Seielstad; Rene E M Toes; Elizabeth W Karlson; Ann B Begovich; Lars Klareskog; Peter K Gregersen; Mark J Daly; Robert M Plenge Journal: Nat Genet Date: 2008-09-14 Impact factor: 38.330
Authors: Anne Barton; Wendy Thomson; Xiayi Ke; Steve Eyre; Anne Hinks; John Bowes; Laura Gibbons; Darren Plant; Anthony G Wilson; Ioanna Marinou; Ann Morgan; Paul Emery; Sophia Steer; Lynne Hocking; David M Reid; Paul Wordsworth; Pille Harrison; Jane Worthington Journal: Hum Mol Genet Date: 2008-04-22 Impact factor: 6.150
Authors: C A Wijbrandts; M G W Dijkgraaf; M C Kraan; M Vinkenoog; T J Smeets; H Dinant; K Vos; W F Lems; G J Wolbink; D Sijpkens; B A C Dijkmans; P P Tak Journal: Ann Rheum Dis Date: 2007-11-29 Impact factor: 19.103
Authors: Anne Barton; Wendy Thomson; Xiayi Ke; Steve Eyre; Anne Hinks; John Bowes; Darren Plant; Laura J Gibbons; Anthony G Wilson; Deborah E Bax; Ann W Morgan; Paul Emery; Sophia Steer; Lynne Hocking; David M Reid; Paul Wordsworth; Pille Harrison; Jane Worthington Journal: Nat Genet Date: 2008-09-14 Impact factor: 38.330
Authors: A Ferreiro-Iglesias; A Montes; E Perez-Pampin; J D Cañete; E Raya; C Magro-Checa; Y Vasilopoulos; T Sarafidou; R Caliz; M A Ferrer; B Joven; P Carreira; A Balsa; D Pascual-Salcedo; F J Blanco; M J Moreno-Ramos; A Fernández-Nebro; M C Ordóñez; J J Alegre-Sancho; J Narváez; F Navarro-Sarabia; V Moreira; L Valor; R García-Portales; A Marquez; J Martin; J J Gómez-Reino; A Gonzalez Journal: Pharmacogenomics J Date: 2015-04-21 Impact factor: 3.550